ATE227278T1 - Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression - Google Patents

Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression

Info

Publication number
ATE227278T1
ATE227278T1 AT97919371T AT97919371T ATE227278T1 AT E227278 T1 ATE227278 T1 AT E227278T1 AT 97919371 T AT97919371 T AT 97919371T AT 97919371 T AT97919371 T AT 97919371T AT E227278 T1 ATE227278 T1 AT E227278T1
Authority
AT
Austria
Prior art keywords
treating depression
substituted benzylamine
benzylamine derivatives
derivatives
substituted
Prior art date
Application number
AT97919371T
Other languages
German (de)
English (en)
Inventor
Dirk Casimir Maria Leysen
Gerardus Stephanus Franc Ruigt
Joannes Theodorus Mari Linders
Fredericus Antonius Dijcks
Simon James Anthony Grove
Duncan Robertson Rae
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE227278T1 publication Critical patent/ATE227278T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
AT97919371T 1996-04-19 1997-04-15 Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression ATE227278T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201065 1996-04-19
PCT/EP1997/001904 WO1997040027A1 (en) 1996-04-19 1997-04-15 Substituted benzylamines and their use for the treatment of depression

Publications (1)

Publication Number Publication Date
ATE227278T1 true ATE227278T1 (de) 2002-11-15

Family

ID=8223896

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97919371T ATE227278T1 (de) 1996-04-19 1997-04-15 Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression

Country Status (25)

Country Link
EP (1) EP0898566B1 (zh)
JP (1) JP4008033B2 (zh)
CN (1) CN1139580C (zh)
AR (1) AR006719A1 (zh)
AT (1) ATE227278T1 (zh)
AU (1) AU725847B2 (zh)
BR (1) BR9708790A (zh)
CA (1) CA2251820C (zh)
CZ (1) CZ295747B6 (zh)
DE (1) DE69716896T2 (zh)
DK (1) DK0898566T3 (zh)
ES (1) ES2186888T3 (zh)
HK (1) HK1018271A1 (zh)
HU (1) HU224637B1 (zh)
ID (1) ID17723A (zh)
IL (1) IL120669A (zh)
NO (1) NO311976B1 (zh)
NZ (1) NZ332334A (zh)
PL (1) PL192561B1 (zh)
PT (1) PT898566E (zh)
RU (1) RU2179553C2 (zh)
TR (1) TR199802104T2 (zh)
TW (1) TW498070B (zh)
WO (1) WO1997040027A1 (zh)
ZA (1) ZA973209B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080773A (en) * 1997-10-14 2000-06-27 Akzo Nobel, N.V. Benzylamine derivatives which are useful in treating psychiatric disorders
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
WO2001019821A1 (en) * 1999-09-14 2001-03-22 Aventis Pharmaceuticals Inc. Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as d4 antagonists
US7125903B1 (en) 1999-09-14 2006-10-24 Aventis Pharmaceuticals Inc. Thienoisoxazolyl-and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists
US7253165B2 (en) 1999-09-14 2007-08-07 Aventis Pharmaceuticals Inc. Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists
US7091199B1 (en) 1999-09-14 2006-08-15 Aventis Pharmaceuticals Inc. Thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives useful as d4 antagonists
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
EP1925305A1 (en) * 2006-10-23 2008-05-28 N.V. Organon Ih channel inhibitors for the promotion of wakefulness
US8013165B2 (en) 2008-12-24 2011-09-06 Astrazeneca Ab Ethanamine compounds and methods of using the same 545
US8637551B2 (en) 2009-07-07 2014-01-28 Merck Sharp & Dohme B.V. 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives
CN102942464B (zh) * 2012-12-06 2015-04-08 西北师范大学 化合物1-(2-卤苯基)-3-甲基-丁酮-1的合成方法
CN112300061B (zh) * 2020-10-06 2022-02-18 大连理工大学 一种含氮杂环二芳酮化合物的制备方法
GB202103012D0 (en) 2021-03-03 2021-04-14 King S College London Compounds
GB202103008D0 (en) 2021-03-03 2021-04-14 King S College London Compounds
GB202103017D0 (en) 2021-03-03 2021-04-14 King S College London Compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980365A (en) * 1987-07-13 1990-12-25 Hoechst-Roussel Pharmaceuticals Inc. N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
NO984836L (no) 1998-12-16
CZ295747B6 (cs) 2005-10-12
WO1997040027A1 (en) 1997-10-30
HUP9901434A3 (en) 2001-11-28
HUP9901434A2 (hu) 1999-08-30
RU2179553C2 (ru) 2002-02-20
DK0898566T3 (da) 2003-03-03
NO311976B1 (no) 2002-02-25
CA2251820C (en) 2007-03-27
TR199802104T2 (xx) 2000-09-21
NZ332334A (en) 2000-06-23
ID17723A (id) 1998-01-22
TW498070B (en) 2002-08-11
EP0898566A1 (en) 1999-03-03
CN1139580C (zh) 2004-02-25
CA2251820A1 (en) 1997-10-30
HU224637B1 (hu) 2005-12-28
BR9708790A (pt) 1999-08-03
PL192561B1 (pl) 2006-11-30
PT898566E (pt) 2003-03-31
IL120669A0 (en) 1997-08-14
ES2186888T3 (es) 2003-05-16
PL329348A1 (en) 1999-03-29
AU725847B2 (en) 2000-10-19
ZA973209B (en) 1997-11-20
EP0898566B1 (en) 2002-11-06
DE69716896T2 (de) 2003-07-24
JP4008033B2 (ja) 2007-11-14
IL120669A (en) 2001-04-30
CN1219169A (zh) 1999-06-09
HK1018271A1 (en) 1999-12-17
NO984836D0 (no) 1998-10-16
AR006719A1 (es) 1999-09-08
CZ334998A3 (cs) 1999-06-16
JP2000508672A (ja) 2000-07-11
DE69716896D1 (de) 2002-12-12
AU2387097A (en) 1997-11-12

Similar Documents

Publication Publication Date Title
DE69720463T2 (de) Sulfonamid-derivate und ihre verwendung zur behandlung von zns-erkrankungen
DE69704877D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose
DE69831755D1 (de) Optoakustische kontrastmittel und anwendungsverfahren
ATE235236T1 (de) Unsubstituierte polydiallylaminen zur behandlung von hypercholesterolemia
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
NO20003096D0 (no) Sammensetninger og fremgangsmÕter for behandling av ADD
ATA46794A (de) Einrichtung zur behandlung von hautzonen
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
ATE186447T1 (de) Zusammensetzung und verwendung
DE69716896D1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
DE69804659D1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ATE222910T1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE69620914D1 (de) Perfluoralkoxycycloalkancarbonylfluorid-zusammensetzungen und ihre verwendung
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69721756D1 (de) Paroxetine zur behandlung von depression
DE69720600D1 (de) Mittel zur Verhinderung von schlechten Gerüchen
DE69615714D1 (de) Phosphat-zusammensetzung und ihre verwendung
DE69708629D1 (de) Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren
DE69717846D1 (de) Behandlungsverfahren von laktamen
DE69701458D1 (de) Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
ATE346840T1 (de) Aminoalkylphenol-derivate zur behandlung von depression und gedächtnis-funktionsstörung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0898566

Country of ref document: EP